6533b7d1fe1ef96bd125c1d7

RESEARCH PRODUCT

Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update

Cristian MirvaldAlberto BrigantiGuillaume PloussardGiorgio GandagliaRoderick C.n. Van Den BerghIsabel HeideggerDerya TilkiPiet OstHendrik BorgmannCristian SurcelAlexander KretschmerIgor Tsaur

subject

MaleOncologymedicine.medical_specialtyCombination therapyCost effectivenessUrologyAntineoplastic AgentsDiseaselaw.invention03 medical and health sciencesProstate cancerchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumans030212 general & internal medicineBone Density Conservation Agentsbusiness.industryAbiraterone acetateProstatic NeoplasmsBone metastasismedicine.diseaseZoledronic acidOncologychemistry030220 oncology & carcinogenesisDrug Therapy Combinationbusinessmedicine.drug

description

Recently, a plethora of life-prolonging cytotoxic, next-generation hormonal, immunotherapeutical as well as radionuclide therapies has emerged as a standard care for metastasized castration-resistant prostate cancer. Being strikingly effective in cancer control, these novel therapies might in fact exert a beneficial impact on skeletal events. Therefore, combining anticancer drugs with osteoprotective agents might lead to additional clinical advantage but must be weighed against simultaneously exposing patients to serious toxicities. In addition, further survival prolongation by changing treatment paradigm in both metastasized hormone-sensitive and nonmetastatic castration-resistant disease might potentially increase the risk for bone density reduction complications due to a growing efficacy of androgen ablation leading to prolonged exposure. To address both possible indications of combined treatment and to draw practical conclusions, we performed a comprehensive review of the currently available evidence. (C) 2018 Elsevier Inc. All rights reserved.

yearjournalcountryeditionlanguage
2018-11-01Urologic Oncology: Seminars and Original Investigations
https://doi.org/10.1016/j.urolonc.2018.08.016